Federal Trade Commission V. Amgen Inc., et al.

  1. June 23, 2023

    6 States Join FTC's Challenge To Amgen's $28B Horizon Buy

    Illinois and California are among six states that have joined the Federal Trade Commission's antitrust suit against Amgen's planned $28 billion purchase of Horizon Therapeutics, the maker of the drug Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout.

  2. June 12, 2023

    Amgen, Horizon Blast FTC's 'Speculation On Speculation'

    Amgen and Horizon Therapeutics insisted that the Federal Trade Commission's challenge to their merger is undone by real-world market dynamics that make it impractical to bundle products that, as the agency alleges, will force customers to stick with a pair of drug monopolies.

  3. May 18, 2023

    Takeaways From FTC's Challenge Of Amgen Deal

    The Federal Trade Commission's move this week to block Amgen Inc.'s proposed $27.8 billion purchase of Horizon Therapeutics PLC shows an aggressive attack by enforcers on a transaction that may not have gotten much scrutiny in the past.

  4. May 16, 2023

    FTC Challenges $28B Amgen-Horizon Therapeutics Merger

    The Federal Trade Commission on Tuesday sought to shut down U.S. biotechnology company Amgen Inc.'s proposed $27.8 billion purchase of Ireland-based drugmaker Horizon Therapeutics PLC, filing a lawsuit in federal court to block the transaction.